Keynote I: Neoadjuvant Immunotherapy: A Road to Progress - How Far Can It Take Us?

This presentation provides a comprehensive critique of the clinical and preclinical evidence for neoadjuvant immunotherapy. Emphasis is placed on sharpening the definition of immunotherapy, identifying its multi-compartmental effects, and its off-target effects. Designing combination approaches that can leverage a certain immunotherapeutic agent while mitigating the undesired effects is discussed. The need for refined biomarkers that can not only predict response at baseline, but also that that can guide changes in management, as the treatment evolves will also be briefly addressed. 

Target Audience

This meeting was designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Examine the evidence, the endpoints, and the practice of neoadjuvant immunotherapy treatment in HNSCC.
  • Decipher the contribution of neoadjuvant treatment to meaningful outcomes in patient care.
  • Determine key variables, and confounders, that can affect interpretation of neoadjuvant trial data.

 

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 0.75 Certificate of Attendance
    This activity was designated for 0.75 AMA PRA Category 1 Credit™.
Course opens: 
02/09/2026
Course expires: 
03/01/2028
Cost:
$0.00
Part of: 
2026 Multidisciplinary Head and Neck Cancers Symposium onDemand
Rating: 
0

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 0.75 Certificate of Attendance
    This activity was designated for 0.75 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.